Laboratory Corporation of America Holdings (LH)
After hours:
| Previous close | 201.61 |
| Open | 201.53 |
| Bid | 0.00 x 800 |
| Ask | 0.00 x 800 |
| Day's range | 201.47 - 206.23 |
| 52-week range | 179.59 - 234.09 |
| Volume | |
| Avg. volume | 809,122 |
| Market cap | 17.377B |
| Beta (5Y monthly) | 1.01 |
| PE ratio (TTM) | 44.05 |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | 2.88 (1.40%) |
| Ex-dividend date | 28 May 2024 |
| 1y target est | N/A |
- PR Newswire
Labcorp to Webcast Its Annual Meeting of Shareholders
Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, today announced that its Annual Meeting of Shareholders will be webcast live on May 14 at 9:00 a.m. ET and can be viewed online on the Labcorp Investor Relations website. An archived replay of the webcast will be available for one year.
- PR Newswire
Invitae Receives Court Approval for Sale to Labcorp
Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, and Invitae (OTC:NVTAQ), a leading medical genetics company, announced today that the United States Bankruptcy Court has approved the previously announced bid by Labcorp to acquire assets of Invitae.
- PR Newswire
Labcorp Receives FDA Approval for First Companion Diagnostic for Use with Pfizer's Newly Approved Gene Therapy to Treat Patients with Hemophilia B
Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, today announced the U.S. Food and Drug Administration (FDA) has approved its nAbCyte™ Anti-AAVRh74var HB-FE Assay, a companion diagnostic (CDx) to determine patient eligibility for treatment with BEQVEZ™ (fidanacogene elaparvovec-dzkt), Pfizer's recently FDA-approved hemophilia B gene therapy.
